Abstract:Objective To evaluate the efficacy and safety of Adefovir dipivoxil in the 52-week treatment of chronic hepatitis B in China.Methods We randomly assigned 480 patients with chronic hepatitis B who were positive for hepatitis B e antigen(HBeAg)in China.During the first 12-week period,480 patients were randomly to receive either 10 mg of adefovir dipivoxil(ADV)or placebo once daily in a 2:1 ratio and in the second period,all patients were accepted ADV for 18 weeks.In the last 12-week stage,all patients treated by ADV were randomly to receive either 10 mg of ADV or placebo in a 2:1 ratio and patients treated by placebo were accepted ADV.The primary end point was serum HBV DNA change during the treatment.The secondary endpoints were ALT normalization rate,HBeAg loss rate and HBeAg seroconversion rate.Results At week 12,median serum hepatitis B virus(HBV)DNA levels of group AAA(ADV-ADV-ADV)and group AAP(ADV-ADV-Placebo) were reduced 3.4 and 3.3 log copies per milliliter,significantly greater than group PAA(Placebo- ADV-ADV)of 0.1 log copies/ml reduction(P<0.05).At week 40,serum hepatitis B virus(HBV) DNA levels of all 3 groups were reduced 4.0～4.6 lg copies/ml.At week 52,median serum HBV DNA levels were reduced 5.0 and 4.5 log copies/ml in group PAA and AAA.Meanwhile,HBV DNA was reduced to level under detection in 30.3% and 28.4% patients of these 2 groups.However,HBV DNA level in group AAP rebound to baseline level and HBV DNA in only 0.8% patients(1/119)of this group was reduced to the level under detection.Alanine aminotransferase levels had normalized at week 52 in 69.2 percent and 78.6 percent of patients of groups PAA and AAA.Comparably.the ALT normalization rate reduced to 21.1%(23/109)at week 52 from 74.3%(81/109).HBeAg loss rate and HBeAg seroconversion rate at 52 week in group PAA were 200% and 17% compared with 13% and 8% in group AAA.However,the HBeAg loss rate and HBeAg seroconversion rate in group AAP were decreased from 14% and 11% at week 40 to 9% and 4% at week 52.No HBV polymerase mutations associated with resistance to ADV were identified.Only 5%～11% patients had at least one adverse event and most of which were mild to moderate.There were no significant differences in the changes in serum creatinine or serum phosphorus values compared with baseline level.Conclusions In Chinese patients with HBeAg-positive chronic hepatitis B,52 weeks of ADV treatment resulted in sig- nificant virologic,and biochemical improvement with good safety profile.No evidence of the emer- gence of adefoyir-resistant HBV polymerase mutations was found.

Fanconi's syndrome caused by adefovir dipivoxil:a case report and literature review

Adefovir induced Fanconi syndrome：case report

Fanconi syndrome complicated with spinal cord diseases and peripheral neuropathy related to adefovir dipivoxil

Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil

A Retrospective Analysis of Adverse Drug Reaction Caused by Adefovir Dipivoxil

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Deferasirox-induced hyperammonemia and Fanconi syndrome: a case report

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

Biopsy-proven Nephrotoxicity Induced by Adefovir

Factors associated with the therapeutic effect of lamivudine-resistant chronic hepatitis B during adefovir dipivoxil therapy

Renal Safety of Adefovir Dipivoxil for Two-Year Treatment in Chinese Patients with Chronic Hepatitis B

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series

[Marked improvement in renal tubular markers after switching from adefovir to tenofovir alafenamide in a case of Fanconi syndrome diagnosed through high ALP levels]

The clinical and pathological features of adefovir dipivoxil-related renal impairment

Nephrogenic Hypophosphatemic Osteomalacia During Adefovir Monotherapy for Chronic Hepatitis B Monoinfection.

Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male

The Clinical Efficacy of the Adefovir Dipivoxii in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China